A. Daigneault
Douglas Mental Health University Institute, Montreal, Quebec
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name A. Daigneault as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:38 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT00958633 · Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder.University of British Columbia · terminated · Bipolar I Disorder · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:38 UTC. The ranking covers the 200 most relevant of 3 PubMed records, and a shared surname and initials can bring in a namesake. All 3 on PubMed
- Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial.Mol Psychiatry · 201644 citationsRCR 2.4
- Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression.N Engl J Med · 202338 citationsRCR 6.6
- Community Pharmacist Training-and-Communication Network and Drug-Related Problems in Patients With CKD: A Multicenter, Cluster-Randomized, Controlled Trial.Am J Kidney Dis · 201731 citationsRCR 2.0